Abstract
Systemic treatment options for patients with locally advanced or metastatic basal cell carcinoma (BCC) are limited, particularly when tumors are refractory to anti-programmed cell death protein-1 (PD-1). A better understanding...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have